Fig. 2From: Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsSurvival after JS001 treatment. a Progression-free survival (PFS) of subjects by histology. b Overall survival (OS) of subjects by histology. Percentages of survival patients are shown at indicated time points. Numbers of patients at risk at indicated time points are shown below the x-axisBack to article page